Company Analysis Nektar Therapeutics
1. Summary
Advantages
- The stock's return over the last year (94.34%) is higher than the sector average (-31.05%).
Disadvantages
- Price (1.03 $) is higher than fair price (0.9236 $)
- Dividends (0%) are below the sector average (0.5473%).
- Current debt level 57.88% has increased over 5 years from 20.4%.
- The company's current efficiency (ROE=-210.75%) is lower than the sector average (ROE=9.61%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Nektar Therapeutics | Healthcare | Index | |
|---|---|---|---|
| 7 days | -12% | -22.6% | 2.6% |
| 90 days | -22% | -35.5% | 7.6% |
| 1 year | 94.3% | -31% | 28.9% |
NKTR vs Sector: Nektar Therapeutics has outperformed the "Healthcare" sector by 125.39% over the past year.
NKTR vs Market: Nektar Therapeutics has outperformed the market by 65.43% over the past year.
Stable price: NKTR is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: NKTR with weekly volatility of 1.81% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (1.03 $) is higher than the fair price (0.9236 $).
Price is higher than fair: The current price (1.03 $) is 10.3% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (48.72).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (49.05).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (0.7398) is lower than that of the sector as a whole (4.82).
P/BV vs Market: The company's P/BV (0.7398) is lower than that of the market as a whole (3.18).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (1.08) is lower than that of the sector as a whole (33.75).
P/S vs Market: The company's P/S indicator (1.08) is lower than that of the market as a whole (10.24).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-2.37) is higher than that of the sector as a whole (-22.17).
EV/Ebitda vs Market: The company's EV/Ebitda (-2.37) is lower than that of the market as a whole (28.35).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -7.58% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-7.58%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (123.79%).
5.4. ROE
ROE vs Sector: The company's ROE (-210.75%) is lower than that of the sector as a whole (9.61%).
ROE vs Market: The company's ROE (-210.75%) is lower than that of the market as a whole (10.67%).
5.5. ROA
ROA vs Sector: The company's ROA (-69.36%) is lower than that of the sector as a whole (0.3443%).
ROA vs Market: The company's ROA (-69.36%) is lower than that of the market as a whole (6.44%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-49.32%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (-49.32%) is lower than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5473%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Selling More insider purchases by 171.92% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 24.12.2024 | Wilson Mark Andrew Chief Legal Officer |
Sale | 0.89 | 14 738 | 16 560 |
| 23.12.2024 | Wilson Mark Andrew Chief Legal Officer |
Sale | 0.9 | 30 062 | 33 402 |
| 23.12.2024 | Wilson Mark Andrew Officer |
Purchase | 0.9 | 30 062 | 33 402 |
| 19.12.2024 | Zalevsky Jonathan Chief R&D Officer |
Sale | 0.94 | 48 048 | 51 115 |
| 19.12.2024 | Zalevsky Jonathan Officer |
Purchase | 0.94 | 48 048 | 51 115 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
